A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Bradley J. Monk(The US Oncology Network), James Kauderer(NRG Oncology), Katherine Moxley(University of Oklahoma Health Sciences Center), Albert J. Bonebrake(Cancer Research for the Ozarks), Summer Dewdney(Rush University Medical Center), Angeles Alvarez Secord(Duke Medical Center), Frederick R. Ueland(University of Kentucky), Carolyn M. Johnston(VA Ann Arbor Healthcare System), Carol Aghajanian(Memorial Sloan Kettering Cancer Center)

Gynecologic Oncology

October 8, 2018

10.1016/j.ygyno.2018.10.001

Cited by 118

Abstract

Related Papers

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al.|European Journal of Cancer|2008|29.3k

Optimal two-stage designs for phase II clinical trials

Richard Simon|Controlled Clinical Trials|1989|3.6k

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial

Éric Pujade-Lauraine, Felix Hilpert, B. Weber et al.|Journal of Clinical Oncology|2014|1.6k

Latest research and treatment of advanced-stage epithelial ovarian cancer

Robert L. Coleman, Bradley J. Monk, Anil K. Sood et al.|Nature Reviews Clinical Oncology|2013|497

Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

Steven O’Day, Alexander M.M. Eggermont, Vanna Chiarion‐Sileni et al.|Journal of Clinical Oncology|2013|380